Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii

In a previous study, we reported that human milk oligosaccharides (HMOs) isolated from five donor milk samples possessed antimicrobial and antibiofilm activity against Streptococcus agalactiae, also known as Group B Streptococcus or GBS. Herein, we present a broader evaluation of the antimicrobial a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS infectious diseases 2018-03, Vol.4 (3), p.315-324
Hauptverfasser: Ackerman, Dorothy L, Craft, Kelly M, Doster, Ryan S, Weitkamp, Jörn-Hendrik, Aronoff, David M, Gaddy, Jennifer A, Townsend, Steven D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 324
container_issue 3
container_start_page 315
container_title ACS infectious diseases
container_volume 4
creator Ackerman, Dorothy L
Craft, Kelly M
Doster, Ryan S
Weitkamp, Jörn-Hendrik
Aronoff, David M
Gaddy, Jennifer A
Townsend, Steven D
description In a previous study, we reported that human milk oligosaccharides (HMOs) isolated from five donor milk samples possessed antimicrobial and antibiofilm activity against Streptococcus agalactiae, also known as Group B Streptococcus or GBS. Herein, we present a broader evaluation of the antimicrobial and antibiofilm activity by screening HMOs from 14 new donors against three strains of GBS and two of the ESKAPE pathogens of particular interest to child health, Staphylococcus aureus and Acinetobacter baumannii. Growth and biofilm assays showed that HMOs from these new donors possessed antimicrobial and antibiofilm activity against all three strains of GBS, antibiofilm activity against methicillin-resistant S. aureus strain USA300, and antimicrobial activity against A. baumannii strain ATCC 19606.
doi_str_mv 10.1021/acsinfecdis.7b00183
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6019282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1972301165</sourcerecordid><originalsourceid>FETCH-LOGICAL-a511t-de4db4cf36b56fcefd5d4229ec9f1de31039ba7c83d5b0860f0dec498ea2be453</originalsourceid><addsrcrecordid>eNp9UctuEzEUHSEQrUq_AAl5yaJp_ZjnBimqCkUq6gJYW9f2ncTFYwfbUym_wtfikBCFDStb97yu7qmqt4xeM8rZDehk_Yja2HTdKUpZL15U51x0YtFz3r08-Z9Vlyk90cIRfVPXzevqjA9s6IvPefVr6bOdrI5BWXAEvCG7ibJhtG4iS53ts81bEkZyP0_gyRfrfpBHZ1chgdZriNZgIrAC61MmX3PETQ46aD3_mTooDoBXBYHNeuuO0BxxTlf7QG095qAKFSNRsMvx1r6pXo3gEl4e3ovq-8e7b7f3i4fHT59vlw8LaBjLC4O1UbUeRauadtQ4msbUnA-oh5EZFIyKQUGne2EaRfuWjtSgrocegSusG3FRfdj7bmY1odHocwQnN9FOELcygJX_It6u5So8y5aygfe8GLw_GMTwc8aU5WSTRufAY5iTZEPHBWWs3WWJPbUcPKWI4zGGUbkrVp4UKw_FFtW70w2Pmr81FsLNnlDU8inM0ZeD_dfyN8H2uGI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1972301165</pqid></control><display><type>article</type><title>Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Ackerman, Dorothy L ; Craft, Kelly M ; Doster, Ryan S ; Weitkamp, Jörn-Hendrik ; Aronoff, David M ; Gaddy, Jennifer A ; Townsend, Steven D</creator><creatorcontrib>Ackerman, Dorothy L ; Craft, Kelly M ; Doster, Ryan S ; Weitkamp, Jörn-Hendrik ; Aronoff, David M ; Gaddy, Jennifer A ; Townsend, Steven D</creatorcontrib><description>In a previous study, we reported that human milk oligosaccharides (HMOs) isolated from five donor milk samples possessed antimicrobial and antibiofilm activity against Streptococcus agalactiae, also known as Group B Streptococcus or GBS. Herein, we present a broader evaluation of the antimicrobial and antibiofilm activity by screening HMOs from 14 new donors against three strains of GBS and two of the ESKAPE pathogens of particular interest to child health, Staphylococcus aureus and Acinetobacter baumannii. Growth and biofilm assays showed that HMOs from these new donors possessed antimicrobial and antibiofilm activity against all three strains of GBS, antibiofilm activity against methicillin-resistant S. aureus strain USA300, and antimicrobial activity against A. baumannii strain ATCC 19606.</description><identifier>ISSN: 2373-8227</identifier><identifier>EISSN: 2373-8227</identifier><identifier>DOI: 10.1021/acsinfecdis.7b00183</identifier><identifier>PMID: 29198102</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject><![CDATA[Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - growth & development ; Anti-Bacterial Agents - isolation & purification ; Anti-Bacterial Agents - pharmacology ; Biofilms - drug effects ; Biofilms - growth & development ; Biological Products - isolation & purification ; Biological Products - pharmacology ; Female ; Humans ; Microbial Sensitivity Tests ; Milk, Human - chemistry ; Oligosaccharides - isolation & purification ; Oligosaccharides - pharmacology ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - growth & development ; Streptococcus agalactiae - drug effects ; Streptococcus agalactiae - growth & development]]></subject><ispartof>ACS infectious diseases, 2018-03, Vol.4 (3), p.315-324</ispartof><rights>Copyright © 2017 American Chemical Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a511t-de4db4cf36b56fcefd5d4229ec9f1de31039ba7c83d5b0860f0dec498ea2be453</citedby><cites>FETCH-LOGICAL-a511t-de4db4cf36b56fcefd5d4229ec9f1de31039ba7c83d5b0860f0dec498ea2be453</cites><orcidid>0000-0003-4587-6121 ; 0000-0001-9753-2801 ; 0000-0001-5362-7235</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.7b00183$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsinfecdis.7b00183$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,315,782,786,887,2767,27083,27931,27932,56745,56795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29198102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ackerman, Dorothy L</creatorcontrib><creatorcontrib>Craft, Kelly M</creatorcontrib><creatorcontrib>Doster, Ryan S</creatorcontrib><creatorcontrib>Weitkamp, Jörn-Hendrik</creatorcontrib><creatorcontrib>Aronoff, David M</creatorcontrib><creatorcontrib>Gaddy, Jennifer A</creatorcontrib><creatorcontrib>Townsend, Steven D</creatorcontrib><title>Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii</title><title>ACS infectious diseases</title><addtitle>ACS Infect. Dis</addtitle><description>In a previous study, we reported that human milk oligosaccharides (HMOs) isolated from five donor milk samples possessed antimicrobial and antibiofilm activity against Streptococcus agalactiae, also known as Group B Streptococcus or GBS. Herein, we present a broader evaluation of the antimicrobial and antibiofilm activity by screening HMOs from 14 new donors against three strains of GBS and two of the ESKAPE pathogens of particular interest to child health, Staphylococcus aureus and Acinetobacter baumannii. Growth and biofilm assays showed that HMOs from these new donors possessed antimicrobial and antibiofilm activity against all three strains of GBS, antibiofilm activity against methicillin-resistant S. aureus strain USA300, and antimicrobial activity against A. baumannii strain ATCC 19606.</description><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - growth &amp; development</subject><subject>Anti-Bacterial Agents - isolation &amp; purification</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Biofilms - drug effects</subject><subject>Biofilms - growth &amp; development</subject><subject>Biological Products - isolation &amp; purification</subject><subject>Biological Products - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Milk, Human - chemistry</subject><subject>Oligosaccharides - isolation &amp; purification</subject><subject>Oligosaccharides - pharmacology</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - growth &amp; development</subject><subject>Streptococcus agalactiae - drug effects</subject><subject>Streptococcus agalactiae - growth &amp; development</subject><issn>2373-8227</issn><issn>2373-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuEzEUHSEQrUq_AAl5yaJp_ZjnBimqCkUq6gJYW9f2ncTFYwfbUym_wtfikBCFDStb97yu7qmqt4xeM8rZDehk_Yja2HTdKUpZL15U51x0YtFz3r08-Z9Vlyk90cIRfVPXzevqjA9s6IvPefVr6bOdrI5BWXAEvCG7ibJhtG4iS53ts81bEkZyP0_gyRfrfpBHZ1chgdZriNZgIrAC61MmX3PETQ46aD3_mTooDoBXBYHNeuuO0BxxTlf7QG095qAKFSNRsMvx1r6pXo3gEl4e3ovq-8e7b7f3i4fHT59vlw8LaBjLC4O1UbUeRauadtQ4msbUnA-oh5EZFIyKQUGne2EaRfuWjtSgrocegSusG3FRfdj7bmY1odHocwQnN9FOELcygJX_It6u5So8y5aygfe8GLw_GMTwc8aU5WSTRufAY5iTZEPHBWWs3WWJPbUcPKWI4zGGUbkrVp4UKw_FFtW70w2Pmr81FsLNnlDU8inM0ZeD_dfyN8H2uGI</recordid><startdate>20180309</startdate><enddate>20180309</enddate><creator>Ackerman, Dorothy L</creator><creator>Craft, Kelly M</creator><creator>Doster, Ryan S</creator><creator>Weitkamp, Jörn-Hendrik</creator><creator>Aronoff, David M</creator><creator>Gaddy, Jennifer A</creator><creator>Townsend, Steven D</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4587-6121</orcidid><orcidid>https://orcid.org/0000-0001-9753-2801</orcidid><orcidid>https://orcid.org/0000-0001-5362-7235</orcidid></search><sort><creationdate>20180309</creationdate><title>Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii</title><author>Ackerman, Dorothy L ; Craft, Kelly M ; Doster, Ryan S ; Weitkamp, Jörn-Hendrik ; Aronoff, David M ; Gaddy, Jennifer A ; Townsend, Steven D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a511t-de4db4cf36b56fcefd5d4229ec9f1de31039ba7c83d5b0860f0dec498ea2be453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - growth &amp; development</topic><topic>Anti-Bacterial Agents - isolation &amp; purification</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Biofilms - drug effects</topic><topic>Biofilms - growth &amp; development</topic><topic>Biological Products - isolation &amp; purification</topic><topic>Biological Products - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Milk, Human - chemistry</topic><topic>Oligosaccharides - isolation &amp; purification</topic><topic>Oligosaccharides - pharmacology</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - growth &amp; development</topic><topic>Streptococcus agalactiae - drug effects</topic><topic>Streptococcus agalactiae - growth &amp; development</topic><toplevel>online_resources</toplevel><creatorcontrib>Ackerman, Dorothy L</creatorcontrib><creatorcontrib>Craft, Kelly M</creatorcontrib><creatorcontrib>Doster, Ryan S</creatorcontrib><creatorcontrib>Weitkamp, Jörn-Hendrik</creatorcontrib><creatorcontrib>Aronoff, David M</creatorcontrib><creatorcontrib>Gaddy, Jennifer A</creatorcontrib><creatorcontrib>Townsend, Steven D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ackerman, Dorothy L</au><au>Craft, Kelly M</au><au>Doster, Ryan S</au><au>Weitkamp, Jörn-Hendrik</au><au>Aronoff, David M</au><au>Gaddy, Jennifer A</au><au>Townsend, Steven D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii</atitle><jtitle>ACS infectious diseases</jtitle><addtitle>ACS Infect. Dis</addtitle><date>2018-03-09</date><risdate>2018</risdate><volume>4</volume><issue>3</issue><spage>315</spage><epage>324</epage><pages>315-324</pages><issn>2373-8227</issn><eissn>2373-8227</eissn><abstract>In a previous study, we reported that human milk oligosaccharides (HMOs) isolated from five donor milk samples possessed antimicrobial and antibiofilm activity against Streptococcus agalactiae, also known as Group B Streptococcus or GBS. Herein, we present a broader evaluation of the antimicrobial and antibiofilm activity by screening HMOs from 14 new donors against three strains of GBS and two of the ESKAPE pathogens of particular interest to child health, Staphylococcus aureus and Acinetobacter baumannii. Growth and biofilm assays showed that HMOs from these new donors possessed antimicrobial and antibiofilm activity against all three strains of GBS, antibiofilm activity against methicillin-resistant S. aureus strain USA300, and antimicrobial activity against A. baumannii strain ATCC 19606.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>29198102</pmid><doi>10.1021/acsinfecdis.7b00183</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-4587-6121</orcidid><orcidid>https://orcid.org/0000-0001-9753-2801</orcidid><orcidid>https://orcid.org/0000-0001-5362-7235</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2373-8227
ispartof ACS infectious diseases, 2018-03, Vol.4 (3), p.315-324
issn 2373-8227
2373-8227
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6019282
source MEDLINE; American Chemical Society Journals
subjects Acinetobacter baumannii - drug effects
Acinetobacter baumannii - growth & development
Anti-Bacterial Agents - isolation & purification
Anti-Bacterial Agents - pharmacology
Biofilms - drug effects
Biofilms - growth & development
Biological Products - isolation & purification
Biological Products - pharmacology
Female
Humans
Microbial Sensitivity Tests
Milk, Human - chemistry
Oligosaccharides - isolation & purification
Oligosaccharides - pharmacology
Staphylococcus aureus - drug effects
Staphylococcus aureus - growth & development
Streptococcus agalactiae - drug effects
Streptococcus agalactiae - growth & development
title Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T15%3A40%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20and%20Antibiofilm%20Activity%20of%20Human%20Milk%20Oligosaccharides%20against%20Streptococcus%20agalactiae,%20Staphylococcus%20aureus,%20and%20Acinetobacter%20baumannii&rft.jtitle=ACS%20infectious%20diseases&rft.au=Ackerman,%20Dorothy%20L&rft.date=2018-03-09&rft.volume=4&rft.issue=3&rft.spage=315&rft.epage=324&rft.pages=315-324&rft.issn=2373-8227&rft.eissn=2373-8227&rft_id=info:doi/10.1021/acsinfecdis.7b00183&rft_dat=%3Cproquest_pubme%3E1972301165%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1972301165&rft_id=info:pmid/29198102&rfr_iscdi=true